These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30041662)

  • 1. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.
    Genescà E; Lazarenkov A; Morgades M; Berbis G; Ruíz-Xivillé N; Gómez-Marzo P; Ribera J; Juncà J; González-Pérez A; Mercadal S; Guardia R; Artola MT; Moreno MJ; Martínez-López J; Zamora L; Barba P; Gil C; Tormo M; Cladera A; Novo A; Pratcorona M; Nomdedeu J; González-Campos J; Almeida M; Cervera J; Montesinos P; Batlle M; Vives S; Esteve J; Feliu E; Solé F; Orfao A; Ribera JM
    J Hematol Oncol; 2018 Jul; 11(1):96. PubMed ID: 30041662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma.
    Laharanne E; Chevret E; Idrissi Y; Gentil C; Longy M; Ferrer J; Dubus P; Jouary T; Vergier B; Beylot-Barry M; Merlio JP
    Mod Pathol; 2010 Apr; 23(4):547-58. PubMed ID: 20118908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
    Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
    Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
    Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G
    Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.
    Iacobucci I; Ferrari A; Lonetti A; Papayannidis C; Paoloni F; Trino S; Storlazzi CT; Ottaviani E; Cattina F; Impera L; Abbenante MC; Vignetti M; Vitale A; Potenza L; Paolini S; Soverini S; Pane F; Luppi M; Foà R; Baccarani M; Martinelli G
    Clin Cancer Res; 2011 Dec; 17(23):7413-23. PubMed ID: 22134481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.
    Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H
    Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Yin and Yang-Like Clinical Implications of the
    González-Gil C; Ribera J; Ribera JM; Genescà E
    Genes (Basel); 2021 Jan; 12(1):. PubMed ID: 33435487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
    Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours.
    Rousseau E; Ruchoux MM; Scaravilli F; Chapon F; Vinchon M; De Smet C; Godfraind C; Vikkula M
    Neuropathol Appl Neurobiol; 2003 Dec; 29(6):574-83. PubMed ID: 14636164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human atherosclerotic plaque.
    Holdt LM; Sass K; Gäbel G; Bergert H; Thiery J; Teupser D
    Atherosclerosis; 2011 Feb; 214(2):264-70. PubMed ID: 20637465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF.
    Pasmant E; Laurendeau I; Héron D; Vidaud M; Vidaud D; Bièche I
    Cancer Res; 2007 Apr; 67(8):3963-9. PubMed ID: 17440112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
    Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
    Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes.
    Wolter M; Reifenberger J; Blaschke B; Ichimura K; Schmidt EE; Collins VP; Reifenberger G
    J Neuropathol Exp Neurol; 2001 Dec; 60(12):1170-80. PubMed ID: 11764089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.
    Endo M; Kobayashi C; Setsu N; Takahashi Y; Kohashi K; Yamamoto H; Tamiya S; Matsuda S; Iwamoto Y; Tsuneyoshi M; Oda Y
    Clin Cancer Res; 2011 Jun; 17(11):3771-82. PubMed ID: 21262917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
    Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
    Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of function tp53 mutations do not accelerate the onset of myc-induced T-cell acute lymphoblastic leukaemia in the zebrafish.
    Gutierrez A; Feng H; Stevenson K; Neuberg DS; Calzada O; Zhou Y; Langenau DM; Look AT
    Br J Haematol; 2014 Jul; 166(1):84-90. PubMed ID: 24690081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
    Laud K; Marian C; Avril MF; Barrois M; Chompret A; Goldstein AM; Tucker MA; Clark PA; Peters G; Chaudru V; Demenais F; Spatz A; Smith MW; Lenoir GM; Bressac-de Paillerets B;
    J Med Genet; 2006 Jan; 43(1):39-47. PubMed ID: 15937071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
    Hutter G; Scheubner M; Zimmermann Y; Kalla J; Katzenberger T; Hübler K; Roth S; Hiddemann W; Ott G; Dreyling M
    Genes Chromosomes Cancer; 2006 Feb; 45(2):203-10. PubMed ID: 16258956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.